23.A tables.docx
Document Details
Uploaded by InvaluableStatistics3928
Tags
Full Transcript
+-----------------------+-----------------------+-----------------------+ | Acetylcholinesterase | Acetylcholinesterase | - Explain the | | Inhibitors | inhibitors reduce | importance of | | | acetylcholine | taking medication | | *D...
+-----------------------+-----------------------+-----------------------+ | Acetylcholinesterase | Acetylcholinesterase | - Explain the | | Inhibitors | inhibitors reduce | importance of | | | acetylcholine | taking medication | | *Drug examples:* | breakdown, whereas | as directed; | | | NMDA receptor | teach about | | donepezil (Aricept) | antagonists limit the | discontinuation | | | effects of glutamate. | and resulting | | galantamine | Both drug classes | decline in | | (Razadyne) | have a modest effect | function. | | | in slowing an | | | rivastigmine (Exelon) | individual's rate of | - Provide patient | | | cognitive decline in | and caregiver | | *N*-Methyl-D-aspartat | AD. | education | | e | | regarding side | | (NMDA) Receptor | *May also be used | effects of | | Antagonists | for:* | dizziness, | | | | headache, GI | | *Drug examples:* | - Vascular dementia | upset, and | | | | fatigue. | | memantine (Namenda) | - Parkinson-related | | | | dementia | - Promote adequate | | Namzaric (combination | | fluid intake. | | NMDA receptor | Combination drug | | | antagonist memantine | donepezil and | - Monitor patient's | | and | memantine (Namzaric) | pulse rate. | | acetylcholinesterase | used only after | | | inhibitor donepezil) | patients have been | - Use with caution | | | stabilized on | in patients with | | | memantine and | respiratory | | | donepezil | conditions (e.g., | | | | asthma, COPD). | | | | | | | | - Avoid the use of | | | | antipsychotics, | | | | beta adrenergic | | | | blockers, | | | | corticosteroids, | | | | and | | | | anticholinergic | | | | drugs because of | | | | their | | | | antagonistic or | | | | synergistic | | | | effects. | +-----------------------+-----------------------+-----------------------+